1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
2024) In Leukemia and Lymphoma(
- Contribution to journal › Article
- 2023
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
-
Mark
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
(
- Contribution to journal › Article
- 2022
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
- 2021
-
Mark
Epidemiology and Etiology of AML
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
(
- Contribution to journal › Article